Watch on Radcliffe Cardiology: www.icrjournal...
In this short interview, Dr Yuhei Kobayashi (Albert Einstein College of Medicine, NY, US) joins us to discuss the findings of a substudy of the FAME 3 trial, which aimed to compare FFR-Guided percutaneous coronary Intervention with coronary artery bypass graft surgery (CABG) in a cohort of patients with multivessel CAD.
In this trial, patients with multivessel disease were randomized to receive either FFR-Guided PCI or CABG. Their MACE outcomes were then compared.
Questions:
1. What was the reasoning for focussing on this cohort of Multivessel CAD Patients?
2. What was the study design and key results?
3. Based on these results, what treatment would you suggest for patients in this cohort?
4. Where are the knowledge gaps? What further study is needed?
Recorded remotely from New York, 2022.
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Негізгі бет TCT 2022: FAME 3: FFR-Guided PCI Vs CABG in Pts With Multivessel CAD | Dr Yuhei Kobayashi
Пікірлер: 1